Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study.

Background: Heart failure (HF) and atrial fibrillation (AF) are common and coexistent conditions.

Hypothesis: To investigate the adverse events and mortality risk factors in patients with AF and HF treated with rivaroxaban in Spain.

Methods: Multicenter, prospective and observational study with a follow-up of 2 years, that included adults, with a diagnosis of nonvalvular AF and chronic HF, anticoagulated with rivaroxaban at least 4 months before being enrolled.